Analyst Explains Why He’s Investing in This Top Biotech ETF
“But this is a subsector that’s been under the mat for quite some time. So it’s nice to see some price action there. So couple things for me.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 300,458 | $50,708,297 | -34% | 0.26% |
| 2. | 266,400 | $44,960,328 | +14% | 0.01% | |
| 3. | 202,900 | $34,243,433 | +43% | 0.06% | |
| 4. | 159,500 | $26,918,815 | -13% | 0% | |
| 5. | Citadel Investment Group Ken Griffin | 111,994 | $18,901,227 | +135% | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 648,103 | $109,439,535 | 2.64% | |
| 2. | 142,013 | $23,978,815 | 5.94% | |
| 3. | 116,115 | $19,606,018 | 1.03% | |
| 4. | 61,497 | $10,383,794 | 0.93% | |
| 5. | 57,940 | $10,235,707 | 0.15% |